Squarepoint’s Biogen BIIB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-5,200
Closed -$915K 4282
2025
Q4
$915K Sell
5,200
-7,800
-60% -$1.27M ﹤0.01% 2698
2025
Q3
$1.82M Sell
13,000
-31,900
-71% -$4.31M ﹤0.01% 2180
2025
Q2
$5.64M Buy
44,900
+33,300
+287% +$4.15M 0.01% 1377
2025
Q1
$1.59M Buy
11,600
+3,600
+45% +$515K ﹤0.01% 2282
2024
Q4
$1.22M Buy
8,000
+6,900
+627% +$1.16M ﹤0.01% 2869
2024
Q3
$213K Buy
+1,100
New +$230K ﹤0.01% 3647
2024
Q2
Sell
-7,800
Closed -$1.68M 4066
2024
Q1
$1.68M Buy
7,800
+2,100
+37% +$492K ﹤0.01% 2206
2023
Q4
$1.47M Sell
5,700
-13,500
-70% -$3.32M ﹤0.01% 2231
2023
Q3
$4.93M Buy
+19,200
New +$5.14M 0.01% 1190
2023
Q2
Sell
-2,200
Closed -$612K 3574
2023
Q1
$612K Sell
2,200
-63,400
-97% -$17.5M ﹤0.01% 2183
2022
Q4
$18.2M Buy
+65,600
New +$18.5M 0.07% 285
2022
Q3
Sell
-5,400
Closed -$1.1M 2998
2022
Q2
$1.1M Buy
5,400
+700
+15% +$143K 0.01% 1539
2022
Q1
$990K Sell
4,700
-172,700
-97% -$37.6M ﹤0.01% 1596
2021
Q4
$42.6M Sell
177,400
-11,000
-6% -$2.83M 0.11% 149
2021
Q3
$53.3M Buy
188,400
+5,400
+3% +$1.77M 0.15% 127
2021
Q2
$63.4M Buy
183,000
+167,800
+1,104% +$50.8M 0.24% 79
2021
Q1
$4.25M Buy
+15,200
New +$4.1M 0.02% 699

Other funds holding BIIB

Squarepoint's BIIB Position: Q1 2026 in Review

Squarepoint reduced its Biogen (BIIB) stake by 75% in Q1 2026, selling an estimated $20.3M and leaving 36,053 shares worth $6.61M. The position accounts for 0.01% of the portfolio, ranked #1310.

Squarepoint first reported a position in BIIB in Q1 2015 and has held it in 35 quarters since. The position peaked at $67.9M in Q1 2024. 1,002 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.

  • Squarepoint held 36,053 shares of Biogen worth $6.61M as of Q1 2026.
  • Squarepoint sold 110,355 Biogen shares in Q1 2026, an estimated $20.3M.
  • Biogen made up 0.01% of Squarepoint's portfolio in Q1 2026, its #1310 holding.
  • Squarepoint first reported a position in Biogen in Q1 2015 and has held it in 35 quarters since.
  • Squarepoint's Biogen position peaked at $67.9M in Q1 2024.
  • 1,002 funds tracked by Wall St. Rank held Biogen as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.